E-LIB Suche - Ergebnisse für: De Felip, E.

1

2MO Amivantamab plus chemotherapy vs chemotherapy as first-..:

Felip, E. ; Shu, C.A. ; Aguilar, A....
ESMO Open. 9 (2024) - p. 102581 , 2024

Link: https://doi.org/10.1016/..

2

59P Datopotamab deruxtecan (Dato-DXd) in patients with prev..:

Girard, N. ; Okamoto, I. ; Lisberg, A.E....
ESMO Open. 9 (2024) - p. 102638 , 2024

Link: https://doi.org/10.1016/..

3

195MO Tarlatamab in previously treated small cell lung canc..:

Hummel, H-D. ; Champiat, S. ; Garcia, M.E. Olmedo...
ESMO Open. 9 (2024) - p. 102768 , 2024

Link: https://doi.org/10.1016/..

4

5MO Effect of amivantamab dose interruptions on efficacy an..:

García Campelo, M.R. ; Cho, B.C. ; Girard, N....
ESMO Open. 9 (2024) - p. 102584 , 2024

Link: https://doi.org/10.1016/..

5

Amivantamab plus chemotherapy with and without lazertinib i..:

Passaro, A. ; Wang, J. ; Wang, Y....
Annals of Oncology. 35 (2024) 1 - p. 77-90 , 2024

Link: https://doi.org/10.1016/..

6

99P Molecular correlates and treatment outcomes of patients..:

Pretelli, G. ; Laimito, K.I. Rojas ; Casal, G. Alonso...
ESMO Open. 9 (2024) - p. 102325 , 2024

Link: https://doi.org/10.1016/..

7

KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G..:

Cassier, P. ; Dooms, C. ; Gazzah, A....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 1 - p. e4-e5 , 2024

Link: https://doi.org/10.1016/..

8

8P Amivantamab plus chemotherapy vs chemotherapy in EGFR-mu..:

Tomasini, P. ; Blasco Cordellat, A. ; Dooms, C....
ESMO Open. 9 (2024) - p. 102587 , 2024

Link: https://doi.org/10.1016/..

9

166P Impact of immunotherapy (IT) on overall survival (OS) ..:

Perez, S.M. Cedres ; Valdivia, A.A. ; Pastrana, J.D. Assaf...
ESMO Open. 9 (2024) - p. 102906 , 2024

Link: https://doi.org/10.1016/..

10

Translational insights and overall survival in the U31402-A..:

Yu, H.A. ; Baik, C. ; Kim, D.-W....
Annals of Oncology. 35 (2024) 5 - p. 437-447 , 2024

Link: https://doi.org/10.1016/..

11

Overall survival and central nervous system activity of cri..:

Michels, S. ; Massutí, B. ; Vasyliv, I....
ESMO Open. 9 (2024) 2 - p. 102237 , 2024

Link: https://doi.org/10.1016/..

12

Antibody–drug conjugates in lung and breast cancer: current..:

Peters, S. ; Loi, S. ; André, F....
Annals of Oncology. 35 (2024) 7 - p. 607-629 , 2024

Link: https://doi.org/10.1016/..

13

103TiP Sotorasib versus pembrolizumab in combination with p..:

Barlesi, F. ; Felip, E. ; Popat, S....
ESMO Open. 9 (2024) - p. 102682 , 2024

Link: https://doi.org/10.1016/..

14

11P Patritumab deruxtecan (HER3-DXd) in previously treated ..:

Hayashi, H. ; Goto, Y. ; Yu, H.A....
ESMO Open. 9 (2024) - p. 102590 , 2024

Link: https://doi.org/10.1016/..

15

Amivantamab plus lazertinib versus osimertinib in first-lin..:

Felip, E. ; Cho, B.C. ; Gutiérrez, V....
Annals of Oncology. , 2024

Link: https://doi.org/10.1016/..